Thus, clarifying the epidemiology of breast cancer in sub-Saharan Africa where CXCR4-using variants are prevalent may help evaluate the feasibility of testing and confirming or refuting this hypothesis. This evidence concerns the gene CXCR4 and breast carcinoma.